ScreenerHero

HCMHutchison China MediTech Limited

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · hutch-med.com
12.63USDMkt Cap: 2.20B $P/E: 126.30

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap2.20B $
Enterprise Value918.83M $
Revenue (TTM)549.12M $
Gross Profit212.16M $
Net Income (TTM)456.91M $
Revenue/Share3.185 USD
Last Price12.63 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.8K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINJP3787000003
Valuation
P/E (Trailing)126.30
P/E (Forward)51.51
PEG—
EV/EBITDA-44.79
EV/Revenue1.67
P/S3.98
P/B1.73
EPS (TTM)0.10
EPS (Forward)0.24
52W Range
12.5650% of range12.70
52W High12.70 USD
52W Low12.56 USD
Profitability
Gross Margin38.68%
Oper. Margin0.31%
EBITDA Margin-3.74%
Profit Margin83.30%
ROE36.91%
ROA26.06%
Growth
Revenue Growth0.20%
Earnings Growth-96.50%
Cash Flow & Leverage
Operating CF-64.66M $
CapEx (TTM)24.15M $
FCF Margin-3.44%
FCF Yield-0.86%
Net Debt-1.28B $
Net Debt/EBITDA62.49
Balance Sheet
Debt/Equity0.08
Current Ratio5.64
Quick Ratio5.45
Book Value/Sh7.255 USD
Cash/Share7.919 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.99 USD
Upside (mean)+66.2%
Target Range11.10 USD – 40.40 USD
$11.10+66.2% to mean$40.40
# Analysts14
Ownership
Shares Out.173.81M
Float104.59M
Insiders0.01%
Institutions2.70%
Short Interest
Short Ratio3.3d
Short % Float0.17%
Short % Out.0.10%
Shares Short180.61K
Short (prev mo.)197.91K
Technical
SMA 5011.23 (+12.5%)
SMA 20013.38 (-5.6%)
Beta0.44
S&P 52W Chg21.00%
Avg Vol (30d)50.30K
Avg Vol (10d)68.50K
Technical Indicators
RSI (14)65.2
MACD0.3696
MACD Signal0.3202
MACD Hist.+0.0494
BB Upper13.20 USD
BB Middle11.96 USD
BB Lower10.72 USD
BB Width20.78%
ATR (14)0.3160 USD
Vol Ratio (20d)0.91x